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We appreciate the thoughtful comments of Dr. Pai regarding our
recent publication in JACC on the up-regulation of low-density
lipoprotein receptor-related protein 5 receptor mediated bone
formation in patients with degenerative valve disease (1). We agree
that there are probably other molecular and cellular targets that
play an important role in the pathogenesis of valvular heart disease
including mechanical factors that mediate shear stress and blood
pressure, cellular targets such as matrix metalloproteinases (2), and
cytokines such as transforming growth factor-beta (3). Our group
has published experimental animal evidence implicating endothelial
nitric oxide (4), early inflammatory markers such as foam cell
formation, high sensitivity C-reactive protein, and cellular prolifera-
tion (5) as additional important modifiable cellular targets in the early
valvular lesion. Our studies have shown a link between lipids and bone
formation in the cellular mechanisms of valvular heart disease (6–8),
which may provide an early target for future therapies.
We would like to respond to Dr. Pai’s question regarding the
predominant cellular process associated with the degree of valvular
heart disease. We and others have found differences in the cellular
processes across the valve leaflets depending on the degree of
disease within the valve (9). We observed phenotypic regional bone
differences in the myxomatous mitral valve leaflets and the calcified
stenotic aortic valves. We found that the myxomatous mitral valve
leaflets had more chondrocytic cells at the leaflet edges where the
leaflet repair was excised. In the calcific aortic valves there was
increased bone formation at the attachment site of the leaflet to the
aorta. We have discovered similar changes in our experimental
models of valvular heart disease (10). We did not test for specific
biochemical changes across the different areas of the valve leaflet
for this study, but we agree that this would be of interest in future
studies. We did test the entire leaflet for the biochemical and
cellular markers that we reported in the recent JACC study. We
hope that ongoing prospective clinical trials testing the effects of
statins in valvular heart disease will shed light on the question of
whether early treatment slows the degenerative process in valves
with more inflammatory and less calcified pathology that may be
more amenable to medical therapy.
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